Intellectual Property
Jun. 15, 2013
Impact of Supreme Court's gene patent ruling uncertain for biotech companies
The U.S. Supreme Court's ruling Thursday that human genes cannot be patented left legal observers divided over how the decision would affect patent strategies of research institutions and biotechnology companies in California.
Daily Journal Staff Writer
The U.S. Supreme Court's ruling Thursday that human genes cannot be patented left legal observers divided over how the decision will affect the patent strategies of research institutions and biotechnology companies in California.
The 22-page ruling, written by Justice Clarence Thomas for a unanimous court, said that spliced genes were indistinguishable from a naturally occurring "product of natu...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In